High Seroprevalence of Anti-SARS-CoV-2 Antibodies in Chelsea, Massachusetts. (9th September 2020)

• Record Type: Journal Article
• Authors: Naranbhai, Vivek; Chang, Christina C; Beltran, Wilfredo F Garcia; Miller, Tyler E; Astudillo, Michael G; Villalba, Julian A; Yang, Diane; Gelfand, Jeffrey; Bernstein, Bradley E; Feldman, Jared; Hauser, Blake M; Caradonna, Timothy M; Alter, Galit; Murali, Mandakolathur R; Jasrasaria, Rashmi; Quinlan, Joan; Xerras, Dean C; Betancourt, Joseph R; Louis, David N; Schmidt, Aaron G; Lennerz, Jochen; Poznansky, Mark C; Iafrate, A John
• Is Part Of: Journal of infectious diseases. Volume 222:Number 12(2020)
• Page Start: 1955
• Page End: 1959
• Publication Date: 2020-09-09
• Subjects: SARS-CoV-2 -- COVID-19 -- antibodies -- serosurveillance -- epidemiology -- validation -- lateral flow assay -- immunoassay -- seroprevalence -- Chelsea Massachusetts; Communicable diseases -- Periodicals; Diseases -- Causes and theories of causation -- Periodicals; Medicine -- Periodicals; Communicable Diseases -- Periodicals; Electronic journals; 616.9
• DOI: 10.1093/infdis/jiaa579
• Languages: English
• ISSNs: 0022-1899

Abstract

Abstract: SARS-CoV-2 antibody testing allows quantitative determination of disease prevalence, which is especially important in high-risk communities. We performed anonymized convenience sampling of 200 currently asymptomatic residents of Chelsea, the epicenter of COVID-19 illness in Massachusetts, by BioMedomics SARS-CoV-2 combined IgM-IgG point-of-care lateral flow immunoassay. The seroprevalence was 31.5% (17.5% IgM + IgG +, 9.0% IgM + IgG −, and 5.0% IgM − IgG + ). Of the 200 participants, 50.5% reported no symptoms in the preceding 4 weeks, of which 24.8% (25/101) were seropositive, and 60% of these were IgM + IgG − . These data are the highest seroprevalence rates observed to date and highlight the significant burden of asymptomatic infection.